（文章来源：证券日报） 证券日报网讯 12月3日晚间，多瑞医药发布公告称，控股股东西藏嘉康时代科技发展有限公司于2025年 11月28日至12月1日合计解除质押15，460，000股，占其所持股份比例33.12%，占公司总股本比例 19.33%。 ...

Core Viewpoint - Duori Pharmaceutical (301075) announced that its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., has completed the release of part of its pledged shares, totaling 15,460,000 shares [1] Summary by Relevant Categories Share Pledge Information - The released pledged shares amount to 15,460,000 shares [1] - After the release, Tibet Jiakang holds a total of 9,134,408 pledged shares, which represents 19.57% of its total holdings [1] - The pledged shares account for 11.42% of the company's total share capital [1]

西藏多瑞医药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于近日接到公司 控股股东西藏嘉康时代科技发展有限公司（以下简称"西藏嘉康"）的 通知，获悉西藏嘉康将其所持有本公司的部分股份办理了解除质押业 务，具体事项如下： 股东 名称 是否为第一 大股东及其 一致行动人 本次解除质押股 份数量（股） 占其所持股 份比例 占公司总股 本比例 起始日 解除日期 质权人 西藏 嘉康 是 3,000,000 6.43% 3.75% 2023/3/29 2025/11/28 江阴市融汇农村小 额贷款有限公司 西藏 嘉康 是 3,300,000 7.07% 4.13% 2023/11/20 2025/11/28 上海源倍国际贸易 有限公司 西藏 嘉康 是 1,500,000 3.21% 1.88% 2024/10/14 2025/11/28 江阴市融汇农村小 额贷款有限公司 西藏 嘉康 是 3,200,000 6.86% 4.00% 2024/12/5 2025/12/1 黄平 西 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-104 西藏多瑞医药股份有限公司 关于使用公司闲置自有资金进行现金管理的进展公告 金管理不涉及关联交易。 三、 投资风险分析及风险控制措施 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开了第二届董事会第二十四次会议、第二届监事会第二十三 次会议审议，通过了《关于使用公司闲置自有资金进行现金管理的议 案》，同意在保证公司及子公司资金流动性及安全性前提下，公司及 子公司拟使用额度不超过人民币 15,000 万元（含本数）的闲置自有 资金进行现金管理，在该额度内资金可以滚动使用，使用期限自董事 会审议通过之日起 12 个月内有效。该事项已经公司董事会、监事会 审议通过。具体内容详见于巨潮资讯网（www.cninfo.com.cn）《关于 使用公司闲置自有资金进行现金管理的议案》（公告编号：2025-094）。 序 号 购买主体 受托方名称 产品名称 金额 （万 元） 产品类型 产品起息 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-103 西藏多瑞医药股份有限公司 关于控股股东及其一致行动人协议转让股份事项取得确认书 暨控制权拟发生变更的进展公告 要约，承诺以上预受要约均为不可撤回且在要约收购期间不得处分。 自协议转让股份过户完成之日至要约收购完成之日，西藏嘉康放弃前 述承诺预受要约 19,440,000 股（占上市公司股份总数的 24.30%）的 表决权。 2025 年 11 月 10 日，西藏嘉康及及其一致行动人舟山清畅与王 庆太及其一致行动人崔子浩、曹晓兵签署了《股份转让协议之补充协 议》，对《股份转让协议》的部分条款进行调整。 本次权益变动后，王庆太、崔子浩、曹晓兵合计将拥有上市公司 29.60%的股份及该等股份对应的表决权，西藏嘉康、舟山清畅合计拥 有上市公司 11.98%的表决权，上市公司控股股东、实际控制人变更 为王庆太、崔子浩、曹晓兵。 具体内容详见公司于 2025 年 10 月 14 日、2025 年 11 月 11 日在 巨潮资讯网（www.cninfo.com.cn）披露的《关于控股股东及其一致行 动人协议转让股份暨控制权拟发生变更的提示性公告》（公告 ...

Core Viewpoint - Duory Pharmaceutical (301075.SZ) has indicated on its interactive platform that the company has not yet developed any products related to influenza medications [1] Group 1 - The company has no current product offerings in the influenza medication sector [1]

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant fluctuations in its financial performance and trading activities, with a notable decrease in revenue and net profit in the recent reporting period [1][2]. Group 2 - On November 11, Duorui Pharmaceutical's stock price increased by 0.02%, with a trading volume of 89.78 million yuan. The financing buy-in amount for the day was 12.24 million yuan, while the financing repayment was 11.49 million yuan, resulting in a net financing buy-in of 0.75 million yuan [1]. - As of November 11, the total financing and securities lending balance for Duorui Pharmaceutical was 190 million yuan, which accounts for 4.20% of its circulating market value, indicating a high level of financing compared to the past year [1]. - The company has not engaged in any securities lending activities on November 11, with both the securities lending repayment and selling amount recorded as zero [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. Group 3 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period. The average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%. The net profit attributable to the parent company was -79.73 million yuan, reflecting a significant year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

Group 1 - The core point of the article is that Duori Pharmaceutical announced a change in control, with three individuals forming a concerted action relationship to acquire a total of 23.68 million shares, representing 29.60% of the total share capital, at a price of 32.064 yuan per share, totaling 759 million yuan [1] - After the completion of this equity change, the three individuals will become the new actual controllers of the company, with Cui Zihao holding 14.90% of the shares as the largest shareholder, Wang Qingtai holding 5.00%, and Cao Xiaobing holding 9.70% [1] - The original shareholders, Xizang Jiakang and Deng Yong, have committed to renouncing their voting rights for 19.44 million shares (24.30% of the total share capital) until the completion of the tender offer [1] Group 2 - Wang Qingtai and Cao Xiaobing also plan to further increase their holdings through a partial tender offer for an additional 24.30% of the shares to solidify their control [1] - The equity change is still subject to the completion of share transfer registration and other procedures, meaning the change in control has not yet been finalized [1]

Core Viewpoint - The control of Duori Pharmaceutical has officially changed hands following a significant share transfer, impacting the company's governance structure and future direction [1] Share Transfer Details - Xizang Jiakang Times Technology Development Co., Ltd. and Zhoushan Qingchang Enterprise Management Partnership (Limited Partnership) collectively reduced their holdings by 23,680,000 shares, representing 29.60% of the total share capital [1] - The transfer price was set at 32.064 yuan per share, resulting in a total transaction value of 759 million yuan [1] - Post-transaction, the combined shareholding of the two entities decreased from 65.72% to 36.12% [1] Voting Rights and Control Change - Xizang Jiakang has relinquished voting rights associated with 19.44 million shares, which accounts for 24.30% of the total share capital [1] - The new shareholders, Wang Qingtai, Cui Zihao, and Cao Xiaobing, now hold a combined 29.60% stake and will exert control through board nominations and senior management arrangements [1] - The original actual controller, Deng Yong, is no longer recognized as the company's actual controller following this change [1] Future Plans - The information disclosure obligors have no plans to increase their holdings in the next 12 months but intend to partially reduce their shares through a tender offer [1]